Molecular imaging of DNA synthesis using a new PET tracer: clinical study of diagnosis and therapeutic assessment for esophageal cancer

Molecular imaging of DNA synthesis using a new PET tracer: clinical study of diagnosis and therapeutic assessment for esophageal cancer - Diagnosis and therapeutic assessment for esophageal cancer with molecular imaging of DNA synthesis

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018058

Enrollment

Registered

2015-07-10

Start date

2015-07-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal cancer

Interventions

The patients undergo both 4DST- and FDG-PET studies. The findings will be compared reciprocally. In the procedure, other examinations including histopathological findings and other radiological images

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patient who is pathologically diagnosed as esophageal cancer. 2) Age, elder than or equal to 20 years. 3) Capability to undergo PET scan. 4) Completed the written informed consent.

Exclusion criteria

Exclusion criteria: 1) Unable to have signed informed consent. 2) Patient with severe comorbid disease including liver dysfunction, renal dysfunction or metabolic damage. 3) Uncontrollable diabetics. 4) Those who are determined as not appropriate for the study by the principal investigator.

Design outcomes

Primary

Measure	Time frame
To explore how 4DST-PET can contribute to initial diagnosis, treatment planning and therapeutic assessment of esophageal cancer.	—

Countries

Japan

Contacts

Public ContactRyogo Minamimoto

National Center for Global Health and Medicine Department of Nuclear Medicine

rminamimoto@hosp.ncgm.go.jp03-3202-7181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026